
Sixuan Qian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7683566/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leukemia Research, 2018, 66, 1-7.	0.8	86
2	Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget, 2015, 6, 6448-6458.	1.8	54
3	TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia. Journal of Hematology and Oncology, 2016, 9, 128.	17.0	36
4	Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 371-377.	1.3	32
5	Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses. PLoS ONE, 2010, 5, e13186.	2.5	27
6	Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen–Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 830-835.	2.0	22
7	Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69Âyears old with newly diagnosed acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2570-2579.	1.3	18
8	An Integrated Regulatory Network Based on Comprehensive Analysis of mRNA Expression, Gene Methylation and Expression of Long Non-coding RNAs (IncRNAs) in Myelodysplastic Syndromes. Frontiers in Oncology, 2019, 9, 200.	2.8	15
9	Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15.	4.0	11
10	The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. Journal of Biomedical Research, 2016, 30, 525.	1.6	10
11	Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia. BMC Cancer, 2018, 18, 1269.	2.6	9
12	Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia. Hematology, 2021, 26, 111-122.	1.5	9
13	The single nucleotide polymorphism and haplotype analysis of MDR1 in Chinese diffuse large B cell lymphoma patients. Biomedicine and Pharmacotherapy, 2015, 73, 24-28.	5.6	8
14	Co-occurrence of <i>KIT</i> and <i>NRAS</i> mutations defines an adverse prognostic core-binding factor acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2428-2437.	1.3	6
15	MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients. Biomedicine and Pharmacotherapy, 2017, 95, 743-748.	5.6	4
16	The combination therapy of imatinib and dasatinib achieves longterm molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia. Journal of Biomedical Research, 2014, 30, .	1.6	1
17	Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-13.	4.0	0